Search company, investor...

Janus Pharmaceuticals

Founded Year



Series A | Alive

Total Raised


Last Raised

$2M | 18 yrs ago

About Janus Pharmaceuticals

Janus Pharmaceuticals Inc. (Janus) is a specialty pharmaceutical company identifying, acquiring and aggressively developing topical prescription products for treatment of skin infections. Determined to be the "Dermal Alternative", Janus has already established a strong intellectual property portfolio for topical anti-infective compounds that would be rapidly commercialized through fast regulatory pathways. Led by an accomplished management team and board located in the US and Japan, Janus has trans-Pacific network and resources in the biopharmaceutical industry.

Headquarters Location

1111 South Arroyo Parkway Suite 200

Pasadena, California, 91105,

United States


Missing: Janus Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Janus Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Janus Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Janus Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Janus Pharmaceuticals News

FiercePharma readers didn't just pick a new Valeant moniker. They have some advice, too

May 15, 2017

by Tracy Staton | May 15, 2017 10:26am This sign will have to change if Valeant decides to rebrand itself, and FiercePharma readers have some advice for the switch. We had two black-and-white winners in our rename-Valeant Pharmaceuticals survey, but with Valeant, shades of gray always come along for the ride. Readers started weighing in on a new name for Valeant earlier this month, after CEO Joseph Papa said the company was seriously considering a rebrand, for obvious reasons. Valeant’s image has gone off a cliff the past couple of years, along with its share price. Almost one-quarter of the 624 survey respondents picked Papa Joe’s as their favorite, clearly in the mood for funny over functional. Exactly one-fifth chose Janus Pharmaceuticals, a more plausible solution (though with a couple of caveats, as readers pointed out). Why Papa Joe’s? It refers, of course, to Valeant CEO Joseph Papa, who took the helm after J. Michael Pearson bowed out. “Clever,” one reader commented. “How can you not pick this one?” several others said. And this voter had a rationale: “Because I think they are a joke—so their name should reflect that." As for Janus, more than one reader pointed out that it’s taken, or that it sounds too similar to “Janssen,” the Johnson & Johnson pharma unit. But one reader thought that mental association could be a plus. “People might might mistake it for Janssen, and that could be a good thing,” the comment said. And here’s where shades of gray come in. Janus is the god of rebirth—a fact cheered by many of those who voted for it, given Valeant’s need to be reborn—but as a few readers pointed out, he comes with some baggage. “Two-faced!” one reader said. "I find it double-faced to slap a new (wine) label onto the same old bottle of vinegar,” another said. Vinegar may be a mild name for it. You'll recall that Valeant's reputation took a long slide as it faced criticism for aggressive price hikes, investigations into its relationship with the shady specialty pharmacy Philidor, hearings on Capitol Hill, and mounting concern about the massive amount of debt it piled up as it snapped up smaller companies, cut jobs, raised prices and went on to the next deal. Still, voters who backed Janus emphasized the positive face, and as one noted, it doesn’t necessarily mean Valeant’s actually reborn already. “Aspirational,” the voter said, adding that the company needs to promise a metamorphosis “to help boost morale for their employees more than anything else.” The most impassioned responses, however, came from backers of Icarus—precisely for the uncertainty built in. “Icarus can serve as a warning for further hubris,” a voter said. And another contended that Valeant “has flown too high on many points. A signal that the sky may NOT be the limit.”  To another reader, Icarus captured the company’s daunting task. Rehabbing its reputation will take more than a new logo, and Valeant is likely to be hampered by its past until it proves it’s really changing its ways. “They can't just change their name. They have to change their behaviors. They have no values,” the reader said. “Thus, cruising too close to the sun … got to live with those wings for now.” RELATED:  We asked, you brainstormed: Witty, insulting and serious nominees for Valeant's new name Another concurred, critiquing the company’s growth-by-M&A approach, which yielded big stock gains and many congratulatory slaps on the back for then-CEO Michael Pearson. “It’s the perfect, fitting name for a fraudulent company that always pretended to be better and more advanced than the industry it operated in,” the comment stated. “Their model was a consultant’s dream, but the reality was they were always going to get scorched.” Meanwhile, more than a few readers saw the vote as a referendum on our taste. “Clearly, you eliminated all the fun ones, but of the six lame ones you're offering up here, this is the least awful one,” one voter wrote. (For the record, the least awful one was Phoenix Pharmaceuticals.) Another voter, who picked Salubrix, called it “the least pretentious name,” and added “I would have preferred Valeant McValeantface instead.” Others lamented the lack of a few other nominations, among them Shkreliant, referring to price-hiking Martin Shkreli. Read more on

Janus Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Janus Pharmaceuticals founded?

    Janus Pharmaceuticals was founded in 2004.

  • Where is Janus Pharmaceuticals's headquarters?

    Janus Pharmaceuticals's headquarters is located at 1111 South Arroyo Parkway, Pasadena.

  • What is Janus Pharmaceuticals's latest funding round?

    Janus Pharmaceuticals's latest funding round is Series A.

  • How much did Janus Pharmaceuticals raise?

    Janus Pharmaceuticals raised a total of $2M.

  • Who are the investors of Janus Pharmaceuticals?

    Investors of Janus Pharmaceuticals include Nexus Finance, Private Equity Japan, HS Investments and Tsunami Investment Partnership.

  • Who are Janus Pharmaceuticals's competitors?

    Competitors of Janus Pharmaceuticals include Bloomage BioTech, Orexigen Therapeutics, KemPharm, Excaliard Pharmaceuticals, Anadys Pharmaceuticals and 12 more.

Compare Janus Pharmaceuticals to Competitors

Sound Pharmaceuticals

Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

Eurand S.p.A

The company are a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products using the company's drug formulation technologies. The company are dedicated to the continued development and commercialization of products that better satisfy patients' needs. The company's research efforts are focused on the development of treatment options with enhanced efficacy, safety and convenient dosing. The company have a pipeline of products in development for ourselves and the company's co-development collaborators.

Selectx Pharmaceuticals

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.

Clal Biotechnology Industries

Clal Biotechnology Industries is a public investment firm targeting pre-clinical, seed, start-up, early venture, emerging growth and growth capital stages of financing that was founded in 1998 and based in Tel Aviv, Israel. Clal primarily invests in biopharmaceutical and biotech companies. Generally, Clal Biotechnogy Industries looks to invest up to $10 million per company and prefers to be lead investor and take a board seat. It also seeks to take a majority share in its portfolio companies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.